TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23694974

Group type: EXPERIMENTAL
Intervention: Botox® at 25 U/ml
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dysport® at approximately 100 U/ml
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Xeomin® at 25 U/ml
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NeuroBloc® at 50 U/ml
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of mean anhidrotic area per unit for 100 U/ml of each product
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of optimal concentration for each product
Number of subjects: 20
Study: 22151935

Group type: EXPERIMENTAL
Intervention: Topically applied creatine-containing face-care formulation for 6 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cultured human dermal fibroblasts supplemented with creatine
Number of subjects: 43
Study: 19192466

Group type: EXPERIMENTAL
Intervention: Mirtazapine 30 mg at bedtime for 30 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (untreated depressed patients)
Number of subjects: 28
Study: 17143960

Group type: EXPERIMENTAL
Intervention: Splenectomy with endoscopic variceal ligation (EVL)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Hassab's operation (splenectomy with pericardial devascularization)
Number of subjects: 103
Study: 15496222

Group type: EXPERIMENTAL
Intervention: Donepezil HCl (5 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11211743

Group type: EXPERIMENTAL
Intervention: Low concentration/high volume group (LC/HV, 240 ml of total volume and 5 ml.h‐1 of infusion rate, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High concentration/low volume group (HC/LV, 96 ml of total volume and 2 ml.h‐1 of infusion rate, n = 20)
Number of subjects: 40
Study: 9951744

Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue
Number of subjects: 14

Group type: COMPARATOR
Intervention: Second intention healing
Number of subjects: 14
Study: 7811482

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 120
Study: 3262029

Group type: EXPERIMENTAL
Intervention: Rose bengal staining
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Schirmer's test
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Marginal tear film assessment
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Tear break-up time assessment
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Slit lamp examination
Number of subjects: 104
Study: 29529870

Group type: EXPERIMENTAL
Intervention: Task group (n=51) - task-oriented circuit gait training with caregiver
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Strength group (n=45) - strength training of lower extremities while sitting and lying
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (n=48) - one 90-minute educational session on stroke management
Number of subjects: 144
Study: 27655568

Group type: EXPERIMENTAL
Intervention: Health education about heat wave hazard prevention for 3 months
Number of subjects: 298

Group type: COMPARATOR
Intervention: No intervention measures
Number of subjects: 298
Study: 25514139

Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Quadruple-stranded hamstring tendon (HT)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Double bundle using hamstring tendon (DB)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Patellar tendon (PT) vs Quadruple-stranded hamstring tendon (HT)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Patellar tendon (PT) vs Double bundle using hamstring tendon (DB)
Number of subjects: 330
Study: 23633407

Group type: EXPERIMENTAL
Intervention: H5 DNA priming followed by MIV at intervals of 12-24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H5 DNA priming followed by MIV at intervals of ≤8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: MIV-MIV prime-boost interval of 24 weeks
Number of subjects: 0
Study: 21118565

Group type: EXPERIMENTAL
Intervention: 300 ml of green tea
Number of subjects: 14

Group type: COMPARATOR
Intervention: water (control)
Number of subjects: 14
Study: 18156534

Group type: EXPERIMENTAL
Intervention: Water-fill method (water-filled NGTs)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Traditional method (control group)
Number of subjects: 66
Study: 16553528

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fluoxetine and citalopram
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Shorter-acting SSRIs
Number of subjects: 38

Group type: COMPARATOR
Intervention: Unpublished studies
Number of subjects: 38
Study: 12568411

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 2016

Group type: COMPARATOR
Intervention: No Hormone Replacement Therapy (no HRT)
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: HRT (self-selected)
Number of subjects: 2016

Group type: COMPARATOR
Intervention: No HRT (self-selected)
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Untreated women
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: HRT-treated women
Number of subjects: 2016
Study: 11748515

Group type: EXPERIMENTAL
Intervention: Sufentanil administered by target‐controlled infusion (target effect‐site concentrations ranging from 0.4 to 4.5 ng/mL)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Concomitant medications (lorazepam, morphine‐scopolamine, clonidine, or propofol)
Number of subjects: 103
Study: 9459112

Group type: EXPERIMENTAL
Intervention: Protocol A (standard management): three nebulized albuterol treatments administered 1 hour apart and a chest radiograph obtained within 60 minutes of extubation.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Protocol B: one nebulized albuterol treatment administered immediately after extubation.
Number of subjects: 22
Study: 7840572

Group type: EXPERIMENTAL
Intervention: 1-g intravenous dose of FK-037
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2-g intravenous dose of FK-037
Number of subjects: 6
Study: 2463689

Group type: EXPERIMENTAL
Intervention: Naltrexone (0, 25, 50, or 100 mg)
Number of subjects: 40
Study: 30244369

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study: 28005636

Group type: EXPERIMENTAL
Intervention: High-volume resistance training (VOL, n = 13, 10-12RM, 1-minute rest)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (INT, n = 13, 3-5RM, 3-minute rest)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both training programs (VOL and INT)
Number of subjects: 26
Study: 25370890

Group type: EXPERIMENTAL
Intervention: Nutri-jelly (200-ml box as daily supplement throughout radiotherapy)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no Nutri-jelly)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Study group (Nutri-jelly)
Number of subjects: 74
Study: 25628188

Group type: EXPERIMENTAL
Intervention: Butantan surfactant
Number of subjects: 327

Group type: COMPARATOR
Intervention: Survanta® or Curosurf® (Control)
Number of subjects: 327
Study: 22105015

Group type: EXPERIMENTAL
Intervention: Blue light (LED, emission maximum: 420 nm)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blue light (LED, emission maximum: 453 nm)
Number of subjects: 40
Study: 19608429

Group type: EXPERIMENTAL
Intervention: Leucocyte filtration of concentrated blood (High-Hct)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Leucocyte filtration of diluted blood (Low-Hct)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Concentrated blood (High-Hct)
Number of subjects: 40
Study: 17250965

Group type: EXPERIMENTAL
Intervention: Motor control exercise
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: General exercise
Number of subjects: 240
Study: 15498086

Group type: EXPERIMENTAL
Intervention: Repaglinide dose titration based on post-prandial glucose levels
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Repaglinide dose titration based on pre-prandial glucose levels
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Repaglinide dose titration based on post-prandial glucose levels in metformin-treated individuals
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Repaglinide dose titration based on pre-prandial glucose levels in metformin-treated individuals
Number of subjects: 193

Group type: COMPARATOR
Intervention: Repaglinide dose titration
Number of subjects: 193
Study: 11727073

Group type: EXPERIMENTAL
Intervention: MIST‐VR training (group II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conventional training exercises (group III)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No training (group I)
Number of subjects: 30
Study: 9616508

Group type: COMPARATOR
Intervention: Healthy subjects (controls)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Asthmatic patients
Number of subjects: 93
Study: 8586785

Group type: EXPERIMENTAL
Intervention: Chlorine covers generated by bathing hands in a solution of 2% sodium tosylchloramide for 1 min.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dechlorinated hands (bathing in a solution of 0.5% sodium thiosulphate for 15 s).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorine covers (2% sodium tosylchloramide) on artificially contaminated hands (Escherichia coli).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorine covers (2% sodium tosylchloramide) on resident flora.
Number of subjects: 0
Study: 2665205

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy plus aspirin and risk factor modifications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin plus risk factor modifications
Number of subjects: 0
Study: 767390

Group type: EXPERIMENTAL
Intervention: Active alert hypnotic induction (riding a bicycle ergometer under load, keeping eyes open, receiving suggestions of alertness)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional relaxation induction (standard eye fixation and relaxation induction of the Stanford Hypnotic Susceptibility Scale, Form B)
Number of subjects: 50
Study: 31153107

Group type: EXPERIMENTAL
Intervention: Pirfenidone 2,403 mg/day
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 170
Study: 28382812

Group type: EXPERIMENTAL
Intervention: Wii Fit
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Tetrax biofeedback
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Conventional weight-shifting training
Number of subjects: 37
Study: 25957003

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy (ET)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Portacaval shunt (PCS)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Emergency transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: ET
Number of subjects: 588

Group type: COMPARATOR
Intervention: PCS
Number of subjects: 588
Study: 23462902

Group type: EXPERIMENTAL
Intervention: Jump 1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Jump 3
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Left leg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Landing data
Number of subjects: 20
Study: 21947298

Group type: EXPERIMENTAL
Intervention: Mean hemoglobin A(1c) levels
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: History of macroalbuminuria
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Myocardial scar prevalence
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Mean hemoglobin A(1c)
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Macroalbuminuria
Number of subjects: 1017
Study: 19623570

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Care in accordance with a locally adapted national guideline
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1283
Study: 18254327

Group type: EXPERIMENTAL
Intervention: Pulmicort
Number of subjects: 210

Group type: COMPARATOR
Intervention: Rhinocort
Number of subjects: 210

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 210
Study: 15470301

Group type: EXPERIMENTAL
Intervention: novel therapy that enhances endothelial function and nitric oxide bioavailability
Number of subjects: 0
Study: 11146708

Group type: EXPERIMENTAL
Intervention: External cooling
Number of subjects: 38

Group type: COMPARATOR
Intervention: No antipyretic treatment (Control)
Number of subjects: 38
Study: 9758131

Group type: EXPERIMENTAL
Intervention: Bathing in marine waters contaminated with domestic sewage
Number of subjects: 0
Study: 9188112

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block with adrenaline (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fascia iliaca compartment block without adrenaline (Group P)
Number of subjects: 20
Study: 1827106

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg 12-hourly
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amoxycillin 500 mg 8-hourly
Number of subjects: 50
Study: 7015934

Group type: EXPERIMENTAL
Intervention: Combination regimens (aminophylline + subcutaneously administered epinephrine or inhaled isoproterenol)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Epinephrine alone
Number of subjects: 89
Study: 31084563

Group type: EXPERIMENTAL
Intervention: Photobiomodulation treatment (RTG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Photobiomodulation treatment (LTG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study: 28679189

Group type: EXPERIMENTAL
Intervention: 30 mg dapoxetine two hours before sexual relations for 3 months (Group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dynamic rehabilitative treatment (Group B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment in association with dynamic rehabilitative behavioural treatment for 3 months (Group C)
Number of subjects: 18
Study: 26505826

Group type: EXPERIMENTAL
Intervention: Soy diet (35% animal protein, 35% soy protein, 30% other plant proteins)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control diet (0.8‐g/kg protein, 70% animal and 30% plant proteins)
Number of subjects: 68
Study: 24948345

Group type: EXPERIMENTAL
Intervention: PTH 1-34 delivered via pump
Number of subjects: 12

Group type: COMPARATOR
Intervention: PTH 1-34 delivered via twice-daily injection
Number of subjects: 12
Study: 22632829

Group type: EXPERIMENTAL
Intervention: Percutaneous intervention (PCI)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 195
Study: 20920295

Group type: EXPERIMENTAL
Intervention: Prolastin-C (60 mg/kg by weekly intravenous infusion for 8 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prolastin (60 mg/kg by weekly intravenous infusion for 8 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prolastin-C (double-blind treatment phase only)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prolastin
Number of subjects: 24
Study: 18567886

Group type: EXPERIMENTAL
Intervention: Extended transsternal thymectomy combined with the prednisone protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone protocol alone
Number of subjects: 0
Study: 15625603

Group type: EXPERIMENTAL
Intervention: 18F‐FDG PET
Number of subjects: 84

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Early phase (40 min) 18F‐FDG PET
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Delayed phase (3 h) 18F‐FDG PET
Number of subjects: 84
Study: 12190759

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard laryngeal mask airway
Number of subjects: 20
Study: 10325828

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment strategy with PEEP 15 cm H2O and tidal volume of 18 ml kg‐1 or peak inspiratory pressure of 40 cm H2O
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEEP 5 cm H2O after initial control period without PEEP
Number of subjects: 30

Group type: COMPARATOR
Intervention: ZEEP (no PEEP)
Number of subjects: 30
Study: 8931831

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 1582305

Group type: EXPERIMENTAL
Intervention: Early adjunctive corticosteroids for Pneumocystis pneumonia
Number of subjects: 28
Study: 4076329

Group type: EXPERIMENTAL
Intervention: Lignocaine 250 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lignocaine 50 mg intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indocyanine green 0.15 mg/kg intravenously
Number of subjects: 12
Study: 30394919

Group type: EXPERIMENTAL
Intervention: Dialysate temperature of 35°C
Number of subjects: 21

Group type: COMPARATOR
Intervention: Dialysate temperature of 37°C
Number of subjects: 21
Study: 29577973

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g) + Coenzyme Q10 (200 mg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (4 g olive oil)
Number of subjects: 85
Study: 26446328

Group type: EXPERIMENTAL
Intervention: 5 mg solifenacin per day
Number of subjects: 119

Group type: COMPARATOR
Intervention: 4 mg fesoterodine per day
Number of subjects: 119
Study: 24092385

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 44

Group type: COMPARATOR
Intervention: Calcineurin inhibitor (CsA)
Number of subjects: 44
Study: 22460670

Group type: EXPERIMENTAL
Intervention: Gold weights (GW)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Platinum chain
Number of subjects: 22
Study: 20001977

Group type: EXPERIMENTAL
Intervention: 24-hour infusion of short acting insulin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 65
Study: 17588297

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl
Number of subjects: 0
Study: 15562352

Group type: EXPERIMENTAL
Intervention: MRI follow-up in patients with congenital anophthalmos
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Treatment with orbital expanders
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MRI orbital volumetry
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Self-inflating high, hydrophilic hydrogel expanders
Number of subjects: 18
Study: 11834235

Group type: EXPERIMENTAL
Intervention: MPA+E(2)C injection on Day 7 of the menstrual cycle (delayed-injection group, n = 117)
Number of subjects: 158

Group type: COMPARATOR
Intervention: MPA+E(2)C injection on Day 5 of the menstrual cycle (control group, n = 41)
Number of subjects: 158
Study: 8396204

Group type: EXPERIMENTAL
Intervention: Fluconazole (n = 6)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Amphotericin B and flucytosine (n = 5)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 11
Study: 3526789

Group type: EXPERIMENTAL
Intervention: Continuous positive pressure ventilation at 8 times per minute
Number of subjects: 11

Group type: COMPARATOR
Intervention: Continuous positive pressure ventilation at 16 times per minute
Number of subjects: 11
Study: 30021076

Group type: EXPERIMENTAL
Intervention: Parenteral epinephrine
Number of subjects: 8014

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8014
Study: 27064136

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol 3 g orally on days 1, 3, and 5
Number of subjects: 126

Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg intramuscularly plus azithromycin 1 g orally as a single dose
Number of subjects: 126
Study: 25403144

Group type: EXPERIMENTAL
Intervention: Mentalization-Based Treatment in a day hospitalization setting (MBT-DH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mentalization-Based Treatment in an intensive outpatient setting (MBT-IOP)
Number of subjects: 0
Study: 23372680

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 21769873

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (100 mg kg(‐1))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (50 mg kg(‐1))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (12.5 mg kg(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Folic acid supplementation (0 mg kg(‐1))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (any level)
Number of subjects: 20
Study: 18509121

Group type: EXPERIMENTAL
Intervention: 2 mg prucalopride
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 4 mg prucalopride
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 2 mg and 4 mg prucalopride
Number of subjects: 620
Study: 17142503

Group type: EXPERIMENTAL
Intervention: Orally administered amoxicillin
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Oximetry data
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Clinical parameters assessment after 24 hours
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Baseline vital signs, symptoms, and laboratory data
Number of subjects: 857
Study: 12911410

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed formulas
Number of subjects: 132

Group type: COMPARATOR
Intervention: Cow's milk and/or formula
Number of subjects: 132
Study: 10631825

Group type: EXPERIMENTAL
Intervention: Castor oil (60 mL)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 103
Study: 9182975

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Tamoxifen and Placebo (combined outcomes)
Number of subjects: 1000